Mesoblast Limited (MESO) Launches First Cell Therapy for Children

We recently compiled a list of 10 Best Mid Cap Stocks to Buy According to Billionaires. Mesoblast Limited stands tenth on our list and has launched the first cell therapy for children.

Mesoblast Limited (NASDAQ:MESO) is among the best mid-cap stocks to buy according to billionaires. It is a global leader in developing allogeneic (off-the-shelf) cellular medicines using its proprietary mesenchymal lineage cell technology. The company targets severe inflammatory diseases that lack effective treatment options. Its lead product, Ryoncil (remestemcel-L), became the first and only FDA-approved mesenchymal stromal cell therapy for children with steroid-refractory acute graft versus host disease (GVHD) in March 2025. Following approval, Mesoblast Limited (NASDAQ:MESO) rapidly launched the drug, partnering with over 25 major U.S. transplant centers and securing insurance coverage for over 250 million lives, including mandatory Medicaid coverage in all states.

Ryoncil now benefits from seven years of orphan drug exclusivity and biologic exclusivity until 2036, with intellectual property protection through 2044, effectively limiting competition. The approval marks the foundation of the business’s broader pediatric inflammatory disease franchise, with plans to expand Ryoncil’s use to additional pediatric and adult indications.

A healthcare professional examining T-cell immunotherapy.

The corporation’s manufacturing processes allow scalable production of consistent cell therapies without the need for donor-recipient matching, simplifying access and logistics. The company is also advancing other key candidates: Revascor (rexlemestrocel-L) for ischemic heart failure, which is on track for FDA submission by the end of 2025 under RMAT designation, and a Phase 3 program for rexlemestrocel-L targeting chronic discogenic low back pain, offering a non-opioid alternative for patients.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.